Calliditas Therapeutics Ab (CLTEF) AI-Powered Stock Analysis
See how Calliditas Therapeutics Ab scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
CLTEF●PNK
TechnologySoftware - Application
$0.25
$0.02(9.34%)
U.S. Market opens in 4h 8m
Advertisement
Calliditas Therapeutics Ab (CLTEF)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerCalliditas Therapeutics Ab (CLTEF) Stock Overall Grade
Calliditas Therapeutics Ab’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Calliditas Therapeutics Ab's overall stock rating.
Forecast
C+Score
53/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
56/100Key Ratios
C+Score
55/100Sector Comparison
BScore
65/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Calliditas Therapeutics Ab (CLTEF) AI-Powered Stock Analysis
This asset demonstrates Normal performance with an overall Forecast Score of 53/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (56/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (65/100, B) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests Moderate divergence in outlook.Component Analysis Explained
Understand the key factors behind each Calliditas Therapeutics Ab stock grade, including financials, comparisons, and forecasts.